Answers are grounded in this paper and cite their sources.
Summary: Behbehani and colleagues use mass cytometry to profile the heterogeneity of acute myeloid leukemia (AML) as compared with normal hematopoiesis. By using this approach and characterizing leukemic stem cells, important differences in response to chemotherapy between AML subsets can potentially be explained and new targeted approaches considered. Cancer Discov; 5(9); 912–4.
No takes yet. Share an insight, caveat, or question.
Do et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: